Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

On CAPS, 97% of the 1,514 members who have rated Novartis believe the stock will outperform the S&P 500 going forward. These bulls include Odiseo and All-Star PsychoDr, who is ranked in the top 5% of our community.

Novartis is a pharmaceutical company with a nice dividend, international reach, and generic drug presence. Generics are the wave of the future and any company that can provide lower price medication for an emerging international market community is a strong long term play. Health care will see significant growth going forward, I want in on all aspects of the industry.

What do you think about Novartis, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!